Years ago, most people with MG died from the disease. Since our inception in 1952 the Foundation has led the charge to ensure investments in the world’s most promising scientific endeavors—funding research and bringing together the brightest minds in the field from around the world at scientific seminars.
Research has led to better diagnostic techniques, treatments and therapies, and improved disease management, such that death from MG has become rare. But today’s treatments come with significant side effects, and are only partially effective in managing the life-altering symptoms of MG. More research is needed to find better therapies, and ultimately, a cure and a world without myasthenia gravis.
St. Louis University investigators will look at a new option for patients with myasthenia gravis, a highly debilitating chronic autoimmune disorder that causes severe muscle weakness and fatigue. Read more here.
The mission of ITMIG is to promote the advancement of clinical and basic science pertaining to thymic and other mediastinal malignancies and related conditions. ITMIG is an academic organization that provides structure, organization and scientific rigor to research in these diseases.
ITMIG has been embraced by other professional organizations in related fields, including the Myasthenia Gravis Foundation of America. For more information click here.